Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 2/2019

01-02-2019 | Brief report

Non-alcoholic fatty liver disease and colorectal cancer survival

Authors: Kana Wu, Mike Z. Zhai, Erin K. Weltzien, Elizabeth M. Cespedes Feliciano, Jeffrey A. Meyerhardt, Edward Giovannucci, Bette J. Caan

Published in: Cancer Causes & Control | Issue 2/2019

Login to get access

Abstract

Purpose

Liver diseases including non-alcoholic fatty liver disease (NAFLD) and ensuing alterations to the micro-environment may affect development of liver metastasis. Mirroring the rise in obesity rates, prevalence of NAFLD is increasing globally. Our objective was to examine the association between NAFLD and mortality in colorectal cancer patients.

Methods

Colorectal Cancer-Sarcopenia and Near-term Survival (C-SCANS) is a retrospective cohort study which included 3,262 stage I–III patients, aged 18–80 years, and diagnosed between 2006 and 2011 at Kaiser Permanente Northern California. Cox proportional hazards regression was used to calculate multivariable adjusted hazard ratios (HR) and 95% confidence intervals (CI).

Results

After up to 10 years of follow-up, 879 deaths, including 451 from CRC were identified. Cases diagnosed with NAFLD before and within 1 month after CRC diagnosis (pre-existing NAFLD; n = 83) had a HR of 1.64 (95% CI 1.06–2.54) for overall and a HR of 1.85 (95% CI 1.03–3.30) for CRC-specific mortality compared to those without NAFLD. Findings did not differ significantly by sex, stage, tumor location, and smoking status, and were also similar when restricted to obese patients only.

Conclusions

Independent of body mass index and prognostic indicators, CRC patients with pre-existing NAFLD had a worse prognosis than those without NAFLD.
Appendix
Available only for authorised users
Literature
1.
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66(4):683–691CrossRefPubMed
2.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A (2017) Colorectal cancer statistics. Cancer J Clin 67(3):177–193CrossRef
3.
4.
Lieber MM (1957) The rare occurrence of metastatic carcinoma in the cirrhotic liver. Am J Med Sci 233(2):145–152CrossRefPubMed
5.
Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, Nguyen MH (2017) Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS ONE 12(3):e0173499CrossRefPubMedPubMedCentral
6.
Min YW, Yun HS, Chang WI, Kim JY, Kim YH, Son HJ, Kim JJ, Rhee JC, Chang DK (2012) Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol 36(1):78–83CrossRefPubMed
7.
You J, Huang S, Huang GQ, Zhu GQ, Ma RM, Liu WY, Shi KQ, Guo GL, Chen YP, Braddock M, Zheng MH (2015) Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis. Medicine 94(5):e479CrossRefPubMedPubMedCentral
8.
Cai B, Liao K, Song XQ, Wei WY, Zhuang Y, Zhang S (2014) Patients with chronically diseased livers have lower incidence of colorectal liver metastases: a meta-analysis. PLoS ONE 9(9):e108618CrossRefPubMedPubMedCentral
9.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84CrossRefPubMed
10.
Rinella M, Charlton M (2016) The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology 64(1):19–22CrossRefPubMed
11.
Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Dannenberg AJ, Kwan ML, Xiao J, Quesenberry C, Weltzien EK, Castillo AL, Caan BJ (2016) Metabolic dysfunction, obesity, and survival among patients with early-stage colorectal cancer. J Clin Oncol 30:3664CrossRef
12.
Meyerhardt JA, Kroenke CH, Prado CM, Kwan ML, Castillo A, Weltzien E, Cespedes Feliciano EM, Xiao J, Caan BJ (2017) Association of weight change after colorectal cancer diagnosis and outcomes in the Kaiser Permanente Northern California Population. Cancer Epidemiol Biomark Prev 26(1):30–37CrossRef
13.
Langley RR, Fidler IJ (2011) The seed and soil hypothesis revisited—the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128(11):2527–2535CrossRefPubMedPubMedCentral
14.
Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343(8910):1405–1410CrossRefPubMed
15.
Murono K, Kitayama J, Tsuno NH, Nozawa H, Kawai K, Sunami E, Akahane M, Watanabe T (2013) Hepatic steatosis Is associated with lower incidence of liver metastasis from colorectal cancer. Int J Colorectal Dis 28(8):1065–1072CrossRefPubMed
16.
VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL (2009) High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol 175(1):355–364CrossRefPubMedPubMedCentral
Metadata
Title
Non-alcoholic fatty liver disease and colorectal cancer survival
Authors
Kana Wu
Mike Z. Zhai
Erin K. Weltzien
Elizabeth M. Cespedes Feliciano
Jeffrey A. Meyerhardt
Edward Giovannucci
Bette J. Caan
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 2/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-018-1095-z

Other articles of this Issue 2/2019

Cancer Causes & Control 2/2019 Go to the issue

Original Paper

Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey

Brief Report

Identifying optimal approaches to scale up colorectal cancer screening: an overview of the centers for disease control and prevention (CDC)’s learning laboratory

Original Paper

Trends in mammography, hormone replacement therapy, and breast cancer incidence and mortality in Canadian women

Original Paper

Rapid increase in endometrial cancer incidence and ethnic differences in New Zealand

Original paper

Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study

Original paper

The association between longer relative leukocyte telomere length and risk of glioma is independent of the potentially confounding factors allergy, BMI, and smoking
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits